Synairgen plc
("Synairgen" or the "Company")
Holding(s) in Company
Southampton, UK , : Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 13 November 2020 that Leonard Licht, a private investor, now holds less than 3% of the Company's issued share capital.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Broker +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser